PLX Protalix Biotherapeutics Inc. (De)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx.

$0.99  -0.01 (-1.00%)
As of 11/26/2021 13:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  04/09/1996
Outstanding shares:  45,556,647
Average volume:  855,602
Market cap:   $45,556,647
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    74365A309
ISIN:        US74365A3095
Valuation   (See tab for details)
PE ratio:   -2.20
PB ratio:   198.00
PS ratio:   0.92
Return on equity:   -9,632.86%
Net income %:   -41.62%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy